Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 plus Gemtuzumab Ozogamicin for Relapsed AML
NCT03904251Phase 1Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2019
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cytarabine and gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose at Day 42. Started Jul 2019; status: terminated.
02
Drugs
cytarabinegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03904251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904251.